Quick Answer
ADC Therapeutics SA reported Operating Income Loss of -$121.50 million for the year ending 2025.
- ADC Therapeutics SA showed an increase of +7.0% in Operating Income Loss from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$50.21 million | Q2 2023: -$39.65 million | Q3 2023: -$36.15 million | Q1 2024: -$33.61 million | Q2 2024: -$29.04 million | Q3 2024: -$35.56 million | Q1 2025: -$28.46 million | Q2 2025: -$44.15 million | Q3 2025: -$30.97 million.
- Over the full 4 years of available data (2022 to 2025), ADC Therapeutics SA's Operating Income Loss has grown by 1.5%.
- Historical annual values: Fiscal year 2025: -$121.50 million | Fiscal year 2024: -$130.65 million | Fiscal year 2023: -$165.99 million | Fiscal year 2022: -$123.34 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: